Annita Tanini Sells 1,224 Shares of Keros Therapeutics (NASDAQ:KROS) Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) VP Annita Tanini sold 1,224 shares of Keros Therapeutics stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total transaction of $12,594.96. Following the sale, the vice president owned 45,144 shares in the company, valued at $464,531.76. This represents a 2.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Keros Therapeutics Trading Up 0.7%

NASDAQ KROS opened at $11.03 on Friday. The stock has a market cap of $218.72 million, a P/E ratio of -2.98 and a beta of 0.99. The company’s fifty day simple moving average is $10.71 and its 200-day simple moving average is $11.84. Keros Therapeutics, Inc. has a 52 week low of $9.69 and a 52 week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. On average, research analysts expect that Keros Therapeutics, Inc. will post -5.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

KROS has been the subject of several recent analyst reports. Leerink Partners lowered their target price on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research note on Tuesday, August 4th. Zacks Research cut Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 29th. Wall Street Zen cut Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, August 16th. Wells Fargo & Company reduced their price target on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a report on Tuesday, August 4th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $20.50.

Institutional Trading of Keros Therapeutics

Several institutional investors have recently added to or reduced their stakes in KROS. Hsbc Holdings PLC boosted its stake in Keros Therapeutics by 29.5% during the 2nd quarter. Hsbc Holdings PLC now owns 69,926 shares of the company’s stock valued at $761,000 after acquiring an additional 15,940 shares during the last quarter. Nantahala Capital Management LLC acquired a new position in Keros Therapeutics during the 2nd quarter worth $15,091,483,000. Empowered Funds LLC bought a new stake in shares of Keros Therapeutics in the 2nd quarter worth about $1,521,000. Public Employees Retirement System of Ohio bought a new stake in shares of Keros Therapeutics in the 2nd quarter worth about $538,000. Finally, Bank of America Corp DE bought a new stake in shares of Keros Therapeutics in the 2nd quarter worth about $334,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.